EVA1A and metabolic dysfunction-associated steatotic liver disease: Our findings not only elucidate EVA1A’s central role in MASLD pathogenesis but also validate the EVA1A–CD36 regulatory axis as a viable therapeutic target against metabolic liver diseases.